Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201310010 Principal Investigator: Bartlett, Nancy
Title: A Phase Ib Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of DCDS4501A in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with B-Cell Non-Hodgkin's Lymphoma
Phase: I Disease Site: Non-Hodgkin's Lymphoma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to test an investigational drug called DCDS4501A, in combination with four other drugs, rituximab (Rituxan®, MabThera®), cyclophosphamide, doxorubicin, and prednisone (when given together, referred to as R-CHP). We want to find out what effects, good and/or bad, these drugs taken together have on you and your cancer. This study will determine a dose that is safe when given in humans.
 
More Information:
clinicaltrials.gov link
Internal Protocol Documents (requires Siteman administrative database password)